BD (NYSE:BDX) announced that it expanded its Class I voluntary recall for its Alaris Pump Module model 8100 infusion system.

Dexcom (Nasdaq:DXCM) today announced plans to unveil its Smart Basal integrated titration module for insulin delivery.

The FDA identified a recall of smartphone apps for Dexcom (Nasdaq:DXCM) continuous glucose monitors as the most serious type.

Insulet (Nasdaq:PODD) has its eyes on future expansion in new geographies, according to some of its leading executives.

A California judge has dismissed several claims against Dexcom (Nasdaq:DXCM) officials related to alleged misrepresentation of sales efforts.

Johnson & Johnson announced today that the FDA approved Inlexzo, its gemcitabine intravesical drug delivery system.

Elutia announced today that it agreed to sell its bioenvelope technologies to Boston Scientific for $88 million.